| Literature DB >> 31911926 |
Meng-Ru Zhan1, Xu Liu1, Ming-Yuan Zhang1, Jun-Qi Niu2.
Abstract
BACKGROUND: Macro-aspartate aminotransferase (AST), a macroenzyme, is a high-molecular mass complex formed by self-polymerization or association with other serum components that are difficult for the kidney to clear, leading to the isolated elevation of serum AST activity. Cases of macro-AST formation are rare, with only 3 published in the English language literature up to September 2019 in China. In this paper, we present a case in which an asymptomatic woman with persistent isolated elevated AST was confirmed as having macro-AST by the polyethylene glycol precipitation method. CASEEntities:
Keywords: Aspartate aminotransferase; Case report; China; Macro-aspartate aminotransferase; Macroenzymes; Polyethylene glycol precipitation method
Year: 2019 PMID: 31911926 PMCID: PMC6940328 DOI: 10.12998/wjcc.v7.i24.4414
Source DB: PubMed Journal: World J Clin Cases ISSN: 2307-8960 Impact factor: 1.337
Laboratory data in the clinic
| AST in U/L | 89.5 (13.0-35.0) | WBC as × 109/L | 4.49 (3.5-9.5) |
| ALT in U/L | 16.1 (7.0-40.0) | RBC as × 109/L | 4.22 (3.8-5.10) |
| GGT in IU/L | 12.6 (7.0-45.0) | Hemoglobin in g/L | 123 (115-150) |
| ALP in IU/L | 47.6 (35.0-100.0) | Platelets as × 109/L | 187 (125-350) |
| ACHE in IU/L | 7194 (4300-12000) | Neutrophils as × 109/L | 2.69 (1.80-6.30) |
| TP in g/L | 74.9 (65.0-85.0) | Lymphocytes as × 109/L | 1.41 (1.10-3.20) |
| ALB in g/L | 44.9 (40.0-55.0) | Monocytes as × 109/L | 0.32 (0.10-0.60) |
| GLB in g/L | 30.0 (20.0-40.0) | ||
| TBIL in μmol/L | 9.4 (6.8-30.0) | ||
| DBIL in μmol/L | 2.8 (0.0-8.6) | CHOL in mmol/L | 4.39 (2.6-6.0) |
| IBIL in μmol/L | 6.6 (5.1-21.4) | TG in mmol/L | 0.62 (0.28-1.80) |
| Enzyme parameter | |||
| CK in U/L | 67 (40-200) | Virology test | |
| CKMB in U/L | 7.2 (0.0-25) | Anti-HAV-IgM | - (-) |
| LDH in U/L | 161 (120-250) | Anti-HEV-IgM | - (-) |
| α-HBDH in U/L | 116 (78.0-182.0) | HBsAg | - (-) |
| MAO in U/L | 3.4 (0.0-12.0) | Anti-HBsAb | + (-) |
| AFU in U/L | 21 (3.0-40.0) | HBeAg | - (-) |
| AMY in U/L | 90 (1-135) | Anti-HBeAb | - (-) |
| LPS in U/L | 46 (5.6-51.3) | Anti-HBcAb | - (-) |
| Anti-HCV | - (-) | ||
| Immunological test | Anti-HIV | - (-) | |
| Anti-dsDNA | - (-) | Anti-TP | - (-) |
| Anti-M2 | - (-) | ||
| Anti-gp210 | - (-) | ||
| Anti-SP100 | - (-) | Liver metabolism test | |
| Anti-SSA-52/Ro52 | - (-) | CER in g/L | 0.28 (0.2-0.6) |
| Anti-Sm | - (-) | SI in μmol/L | 15.6 (7.8-32.2) |
| Anti-nRNP/Sm | - (-) | SF in μmol/L | 43.5 (10-120.0) |
| Anti-LKM | - (-) | TIBC in μg/L | 62.0 (50.0-70.0) |
| Immunoglobulin A in g/L | 2.60 (0.7-4.0) | ||
| Immunoglobulin G in g/L | 15.1 (7.0-16.0) | ||
| Immunoglobulin M in g/L | 0.90 (0.4-2.3) | ||
| Complement C3 in g/L | 1.31 (0.9-1.8) |
AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; GGT: γ-glutamyltransferase; ALP: Alkaline phosphatase; ACHE: Acetylcholinesterase; TP: Total protein; ALB: Albumin; GLB: Globulin; TBIL: Total bilirubin; DBIL: Direct bilirubin; IBIL: Indirect bilirubin; CK: Creatine kinase; CKMB: Creatine kinase isoenzymes; LDH: Lactate dehydrogenase; α-HBDH: α-Hydroxybutyrate Dehydrogenase; MAO: Monoamine oxidase; AFU: α-L- Fucosidase; AMY: Amylase; LPS: Lipase; Anti-dsDNA: Anti-double strand DNA antibody; Anti-M2: Antimitochondrial antibody 2; Anti-Sm: Anti-smooth muscle antibody; WBC: White blood cells; Anti-LKM: Anti liver and kidney microsomes antibody; WBC: White blood cell; RBC: Red blood cells; CHOL: Cholesterol; TG: Triglyceride; anti-HCV: Anti-hepatitis C virus antibody; anti-HIV: Anti-human immunodeficiency virus antibody; Anti-TP: Anti-Treponema pallidum; CER: Ceruloplasmin; SI: Serum iron; SF: Serum ferritin; TIBC: Total iron binding capacity.
Figure 1Changes in the patient’s aspartate aminotransferase activity over a 17-mo period. The horizontal bar represents the upper limit of normal of aspartate aminotransferase (AST).
Precipitation with polyethylene glycol
| Patient | 71.8 | 38.9 | 1.4 | 96.4 | 3.60 |
| Control 1 | 229 | 121.7 | 49.8 | 59.1 | 40.9 |
| Control 2 | 68 | 31 | 17.7 | 42.9 | 57.1 |
Polyethylene glycol precipitation (PEG): 25% PEG centrifuged at 3000 rpm of two control serum samples and samples from the patient with macro-aspartate aminotransferase (AST). AST origin: AST value of the original serum; AST diluted 1/2 (DIL1/2): AST value of serum DIL1/2 with phosphate-buffered saline; AST PEG: AST value after PEG precipitation. PEG-precipitable activity (PPA) = 100 × [(AST DIL1/2−AST PEG)/AST DIL1/2]; AST recovery = 100 × (AST PEG/AST DIL1/2).